Sage Therapeutics (NASDAQ:SAGE) Sets New 52-Week Low at $15.06

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report)'s stock price reached a new 52-week low on Tuesday . The stock traded as low as $15.06 and last traded at $15.27, with a volume of 913976 shares traded. The stock had previously closed at $15.32.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. HC Wainwright lifted their price objective on Sage Therapeutics from $25.00 to $28.00 and gave the company a "neutral" rating in a report on Thursday, February 15th. JPMorgan Chase & Co. boosted their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the stock an "overweight" rating in a report on Tuesday, March 26th. Royal Bank of Canada boosted their target price on shares of Sage Therapeutics from $21.00 to $26.00 and gave the stock a "sector perform" rating in a report on Thursday, February 15th. Morgan Stanley boosted their target price on shares of Sage Therapeutics from $20.00 to $22.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 28th. Finally, StockNews.com upgraded shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, February 15th. Fifteen equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $41.00.

Sage Therapeutics Stock Performance

The company has a market cap of $939.52 million, a price-to-earnings ratio of -1.73 and a beta of 0.86. The business has a 50-day simple moving average of $20.47 and a 200-day simple moving average of $21.05.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($1.28) by $0.73. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The business had revenue of $77.97 million for the quarter, compared to analyst estimates of $60.15 million. During the same quarter last year, the company earned ($2.47) EPS. The business's quarterly revenue was up 2621.5% on a year-over-year basis. Research analysts anticipate that Sage Therapeutics, Inc. will post -6.05 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SAGE. CWM LLC grew its stake in shares of Sage Therapeutics by 274.2% in the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 883 shares during the last quarter. KBC Group NV purchased a new stake in shares of Sage Therapeutics in the fourth quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Sage Therapeutics by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 748 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Sage Therapeutics in the first quarter valued at approximately $34,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Sage Therapeutics by 74.0% in the third quarter. Tower Research Capital LLC TRC now owns 5,050 shares of the biopharmaceutical company's stock valued at $104,000 after buying an additional 2,148 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company's stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.